Patomechanisms of hepatic steatosis;A steatosis kialakulásának patomechanizmusai

Orvosi Hetilap

Volumn 151, Issue 9, 2010, Pages 323-329

  Fülöp, Péter ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

De novo lipogenesis; Fatty acid oxidation; Insulin resistance; Nonalcoholic fatty liver disease; Steatosis; VLDL secretion

Indexed keywords

CYTOCHROME P450 2E1; CYTOCHROME P450 4A; CYTOCHROME P450 4A10; CYTOCHROME P450 4A14; LIVER TRIACYLGLYCEROL LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRUVATE KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALCOHOLISM; COMORBIDITY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; REVIEW; STEATITIS;

CARCINOMA, HEPATOCELLULAR; CHOLESTEROL, VLDL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOGENESIS; LIPOPROTEINS, VLDL; LIVER CIRRHOSIS; LIVER NEOPLASMS; OBESITY; TRIGLYCERIDES;

EID: 77249146926     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28816     Document Type: Review

References (47)

1. The World Health Report 2002. Reducing Risks, Promoting Healthy Life (World Health Organization, Genf, 2002).
2. Clark, J. M., Brancati, F. L., Diehl, A. M.: The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol., 2003, 98, 960-967.
3. Angulo, P.: Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
4. Marchesini, G., Forlani, G.: NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology, 2002, 35, 497-499.
5. Ruhl, C. E., Everhart, J. E.: Epidemiology of nonalcoholic fatty liver. Clin. Liver Dis., 2004, 8, 501-519.
6. Armstrong, G. L., Wasley, A., Simard, E. P. és mtsai: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med., 2006, 144, 705-714.
7. Hagymási K., Reismann P., Rácz K. és mtsa: Az endokrin rend-szer szerepe a nem alkoholos zsírmáj kialakulásában. Orv. Hetil., 2009, 150, 2173-2181.
8. Marchesini, G., Brizi, M., Bianchi, G. és mtsai: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
9. Ábel T., Fehér J.: A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat. Orv. Hetil., 2008, 149, 1299-1305.
10. Reddy, J. K., Rao, M. S.: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Phy-siol. Gastrointest. Liver Physiol., 2006, 290, G852-G858.
11. Bugianesi, E., McCullough, A. J., Marchesini, G.: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42, 987-1000.
12. Paz, K., Hemi, R., LeRoith, D. és mtsai: A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem., 1997, 272, 29911-29918.
13. Lee, J. Y., Cho, H. K., Kwon, Y. H.: Palmitate induces insulin resistance without significant intracellular triglyceride accumulation in HepG2 cells. Metabolism, 2009 [epub ahead of print].
14. Baud, V., Karin, M.: Signal transduction by tumor necrosis factor and its realtives. Trends Cell. Biol., 2001, 11, 372-377.
15. Hotamisligil, G. S.: Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
16. Rui, L., Yuan, M., Frantz, D. és mtsai: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem., 2002, 277, 42394-42398.
17. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J. és mtsai: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115, 1343-1351.
18. Mittendorfer, B., Magkos, F., Fabbrini, E. és mtsai: Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity, 2009, 17, 1872-1877.
19. Lewis, G. F., Carpentier, A., Adeli, K. és mtsa: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev., 2002, 23, 201-229.
20. Bradbury, M. W.: Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G194-G198.
21. Wahren, J., Sato, Y., Ostman, J. és mtsai: Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise. J. Clin. Invest., 1984, 73, 1367-1376.
22. Greco, D., Kotronen, A., Westerbacka, J. és mtsai: Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294, G1281-G1287.
23. Bamba, V., Rader, D. J.: Obesity and atherogenic dyslipidemia. Gastroenterology, 2007, 132, 2181-2190.
24. Browning, J. D., Horton, J. D.: Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114, 147-152.
25. Horton, J. D., Goldstein, J. L., Brown, M. S.: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest., 2002, 109, 1125-1131.
26. Horton, J. D., Shah, N. A., Warrington, J. A. és mtsai: Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA, 2003, 100, 12027-12032.
27. Iizuka, K., Bruick, R. K., Liang, G. és mtsai: Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA, 2004, 101, 7281-7286.
28. Shimomura, I., Bashmakov, Y., Horton, J. D.: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem., 1999, 274, 30028-30032.
29. Yahagi, N., Shimano, H., Hasty, A. H. és mtsai: Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem., 2002, 277, 19353-19357.
30. Kim, J. B., Wright, H. M., Wright, M. és mtsa: ADD1/SREBP-1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA, 1998, 95, 4333-4337.
31. Matsusue, K., Haluzik, M., Lambert, G. és mtsai: Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest., 2003, 111, 737-747.
32. Nakamuta, M., Yada, R., Fujino, T. és mtsai: Changes in the expression of cholesterol metabolism-associated genes in HCV-in-fected liver: a novel target for therapy? Int. J. Mol. Med., 2009, 24, 825-828.
33. Clément, S., Negro, F.: Hepatitis C virus: The viral way to fatty liver. J. Hepatol., 2007, 46, 985-987.
34. Araya, J., Rodrigo, R., Videla, L. A. és mtsai: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond)., 2004, 106, 635-643.
35. Muller, M. J.: Hepatic fuel selection. Proc. Nutr. Soc., 1995, 54, 139-150.
36. Rao, M. S., Reddy, J. K.: PPARα in the pathogenesis of fatty liver disease. Hepatology, 2004, 40, 783-786.
37. Reddy, J. K., Hashimoto, T.: Peroxisomal β-oxidation and peroxi-some proliferator-activated receptor α: an adaptive metabolic system. Annu. Rev. Nutr., 2001, 21, 193-230.
38. Fan, C. Y., Pan, J., Usuda, N. és mtsai: Steatohepatitis, spontaneous peroxisome proliferation and liver tumor sin mice lacking peroxisomal acyl-CoA oxidase. J. Biol. Chem., 1998, 273, 15639-15645.
39. Xu, A., Wang, Y., Keshaw, H. és mtsai: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest., 2003, 112, 91-100.
40. Seo, Y. S., Kim, J. H., Jo, N. Y. és mtsai: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroenterol. Hepatol., 2008, 23, 102-109.
41. Bugianesi, E., Gastaldelli, A., Vanni, E. és mtsai: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia, 2005, 48, 634-642.
42. Kotronen, A., Seppälä-Lindroos, A., Vehkavaara, S. és mtsai: Liver fat and lipid oxidation in humans. Liver Int., 2009, 29, 1439-1446.
43. Parekh, S., Anania, F. A.: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology, 2007, 132, 2191-2207.
44. Fabbrini, E., Sullivan, S., Klein, S.: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology, 2010, 51, 679-689. [Published Online: 9 Sep 2009.].
45. Neuschwander-Tetri, B. A., Caldwell, S. H.: Nonalcoholic steato-hepatitis: summary of an AASLD single topic conference. Hepa-tology, 2003, 37, 1202-1219.
46. Fabbrini, E., Mohammed, B. S., Magkos, F. és mtsai: Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology, 2008, 134, 424-431.
47. Horton, J. D., Shimano, H., Hamilton, R. L. és mtsai: Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest., 1999, 103, 1067-1076.